Education
About Us
Working with TipRanks
Follow Us
Xintela AB (SE:XINT)
:XINT
Top Page
Xintela AB
(Frankfurt:XINT)
Rating:43Neutral
Price Target:―
Xintela AB (XINT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr305.60M
Dividend YieldN/A
Average Volume (3M)680.77K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth5303.85%
EPS Growth55.59%
CountrySE
Employees21
SectorTechnology
Sector Strength84
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding665,798,030
10 Day Avg. Volume630,052
30 Day Avg. Volume680,773
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)-8.82
Price to Sales (P/S)0.00
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Xintela AB Business Overview & Revenue Model
Company DescriptionXintela AB (XINT) is a biotechnology company based in Sweden that focuses on the development and commercialization of cell therapy products and targeted cancer treatments. The company leverages its proprietary marker technology, XINMARK, to identify and select specific cell types for therapeutic use, primarily in the fields of regenerative medicine and oncology. Xintela's core products and services revolve around stem cell-based therapies for osteoarthritis and other musculoskeletal disorders, as well as targeted antibodies for the treatment of aggressive cancers.
How the Company Makes MoneyXintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.
Xintela AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.20M | 78.00K | 0.00 | 0.00 | 0.00 | 38.00K | Gross Profit |
| 2.26M | 78.00K | -3.79M | -3.50M | -3.57M | 5.68M | EBIT |
| -41.46M | -57.24M | -69.06M | -43.56M | -33.90M | -38.05M | EBITDA |
| -39.14M | -53.47M | -64.83M | -57.11M | -30.33M | -33.92M | Net Income Common Stockholders |
| -40.48M | -54.08M | -66.22M | -58.93M | -52.92M | -43.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 20.99M | 7.81M | 8.34M | 9.94M | 33.60M | 412.00K | Total Assets |
| 39.40M | 18.39M | 24.52M | 24.74M | 48.51M | 17.09M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 10.90M | 0.00 | Net Debt |
| -20.99M | -7.81M | -8.34M | -9.94M | -22.70M | -412.00K | Total Liabilities |
| 3.91M | 14.02M | 18.74M | 20.80M | 20.91M | 7.77M | Stockholders Equity |
| 35.48M | 4.38M | 5.78M | 3.95M | 27.61M | 9.32M |
| Cash Flow | Free Cash Flow | ||||
| -17.80M | -53.22M | -39.60M | -44.15M | -21.71M | -32.51M | Operating Cash Flow |
| -17.80M | -53.12M | -39.49M | -42.89M | -21.33M | -30.89M | Investing Cash Flow |
| 0.00 | -104.00K | -27.52M | -1.20M | -329.00K | -2.53M | Financing Cash Flow |
| 7.08M | 51.79M | 64.56M | 20.43M | 54.85M | 2.44M |
Xintela AB Technical Analysis
Positive
0.46
Price Trends
0.41
Positive
0.41
Positive
0.41
Positive
Market Momentum
<0.01
Positive
57.25
Neutral
50.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Positive. The current price of 0.46 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.41, and above the 200-day MA of 0.41, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 57.25 is Neutral, neither overbought nor oversold. The STOCH value of 50.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XINT.
Xintela AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $11.80B | 10.31 | -7.45% | 2.91% | 7.43% | -7.78% | |
48 Neutral | kr379.37M | ― | -47.73% | ― | 45.52% | 93.35% | |
47 Neutral | €78.79M | ― | -69.81% | ― | -17.91% | 22.80% | |
44 Neutral | kr267.41M | ― | -18.79% | ― | ― | 21.85% | |
43 Neutral | €563.30M | ― | -138.29% | ― | ― | 39.92% | |
43 Neutral | kr305.60M | ― | ― | 5303.85% | 55.59% | ||
36 Underperform | €185.74M | ― | -54.29% | ― | -100.00% | -17.35% |
* Technology Sector Average
Performance Comparison
SE:XINT
Xintela AB
0.46
0.20
79.30%
SE:ACE
Ascelia Pharma AB
4.84
-1.68
-25.80%
SE:IMMU
Immunicum AB
5.18
-4.40
-45.93%
SE:ISOFOL
Isofol Medical AB
1.14
0.43
59.55%
SE:NXTCL
NextCell Pharma AB
1.06
-0.45
-29.93%
SE:XBRANE
Xbrane Biopharma AB
0.23
-0.07
-24.18%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.